Eikon Therapeutics, Inc. EIKN
Eikon Therapeutics, Inc. (Nasdaq: EIKN) is an oncology drug developer. Its lead program, EIK1001, is in Phase 2 for First-line advanced melanoma (with pembrolizumab); also NSCLC. Its next catalyst on record is EIK1005 + pembrolizumab (WRN helicase inhibitor combination): Additional results from EIK1005 in combination with pembrolizumab expected in first half 2027. (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: EIK1005 + pembrolizumab (WRN helicase inhibitor combination) — Additional results from EIK1005 in combination with pembrolizumab expected in first half 2027. (H1 2027). 9 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| EIK1001 (TeLuRide-006) | First-line advanced melanoma + pembrolizumab (Phase 2/3 registrational) | small molecule | Phase 2 |
| EIK1001 (TeLuRide-008) | First-line stage 4 NSCLC + pembrolizumab + chemo (Phase 2/3 registrational, first patient dosed July 2026) | small molecule | Phase 2 |
| EIK1001 (TeLuRide-005) | NSCLC + pembrolizumab + chemotherapy (Phase 2, enrollment complete) | small molecule | Phase 2 |
| EIK1003 | Ovarian, breast, prostate, pancreatic cancers (selective PARP1 inhibitor) | small molecule | Phase 2 |
| EIK1004 | Ovarian, breast, prostate, pancreatic cancers incl. brain metastases (brain-penetrant PARP1 inhibitor) | small molecule | Phase 1 |
| EIK1005 | MSI-high solid tumors (WRN helicase inhibitor) | small molecule | Phase 1 |
| EIK1006 | Prostate cancer (next-generation AR antagonist) | small molecule | Pre-clinical |
Recent results and decisions
- Oct 26, 2026positive TeLuRide-005 trial of EIK1001 plus pembrolizumab and chemotherapy in squamous NSCLC showed 72.4% ORR, 100% DCR, and 12.9-month median duration of response with median follow-up of 12.7 months.
With median follow-up of 12.7 months, objective response rate (ORR) for the squamous cohort was 72% and disease control rate (DCR) was 100%, with a median duration of response of 12.9 months.
Filing - Oct 26, 2026positive TeLuRide-005 trial of EIK1001 plus pembrolizumab and chemotherapy in first-line stage 4 NSCLC shows 72.4% ORR in squamous cohort and 55.6% ORR in non-squamous cohort with durable responses and well-tolerated safety profile.
Among participants in the squamous cohort, an ORR of 72.4% and a DCR of 100% were observed, respectively, with a median follow-up of 12.7 months and a median duration of response (DOR) of 12.9 months at the efficacy data cutoff.
Filing - Oct 23, 2026positive EIK1003 monotherapy showed 14.3% ORR overall (31.3% in PARP-naïve patients) with generally well-tolerated safety profile in updated Phase 1/2 data.
Updated data from EIK1003-001 demonstrate that highly selective non-brain-penetrant PARP1 inhibitor EIK1003 as monotherapy (Cohort 1A) was generally well-tolerated across multiple dose levels.
Filing
10 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.